You likely know AGT best from their ongoing work to develop a potential HIV cure. Their lead candidate, AGT103-T, is currently in a Phase 1 trial and has shown encouraging data thus far both in patient safety and T cell responses. The company is currently planning for Phase 2.
Curing HIV is an expensive endeavor, and under Sabrina Campbell’s watchful eye, an innovative service is funding the gene therapy trial that may lead to the end of the HIV epidemic. At the beginning of the COVID-19 pandemic, there was a shortage of PCR testing, which prompted American Gene Technologies® to open its own laboratory to bridge supply and demand. Every dollar of profit from the COVID-19 PCR tests performed in the clinical laboratory pays for the HIV Cure Program’s Phase 1 human trial. With such a critical responsibility, the clinical laboratory must operate uninterrupted, which is why we’re thrilled to highlight Sabrina Campbell, the lab manager who’s aiding a potential HIV cure with COVID-19 testing revenue.
Rockville, Maryland’s American Gene Technologies (AGT™) HIV cure program has been making remarkable progress in its mission to bring a single-dose cure to people living with HIV. That mission is steadily advancing through a successful Phase 1 human clinical trial. The company hopes to begin its Phase 2 study during 2023; this could yield very compelling data towards a functional cure, occurring perhaps as early as the first half of 2024.
We at BioBuzz have always strived to center ourselves around the individuals who have worked to push the biohealth sphere to new heights. Our “5 Questions With…” series embodies this effort as we have highlighted professionals at all levels, from early career to the C-suite, from scientists to business developers to managers and directors. Regardless of position or title, the many individuals highlighted in 2022 are all changemakers in their own right and we greatly appreciate their work and contribution to this series.
Winner of the 2022 BioBuzz Award in media, “The Cure Chronicles” documents the important stories of people living with HIV, HIV advocates, medical experts, public policy makers and others who are united by the common goal of finding a cure for HIV. The series is hosted by AGT’s CEO Jeff Galvin and covers a wide range of HIV topics.
American Gene Technologies®, a clinical-stage biotechnology company based in Rockville, Maryland, has recorded data that meets the primary and secondary endpoints of its AGT103-T Phase 1 trial. The Phase 1 trial demonstrated that AGT103-T — an autologous T cell product that has been modified with the AGT103 lentiviral vector for HIV resistance — was well-tolerated in humans and that these enhanced T cells persist in the body, ready to respond to HIV. Data from this first-in-human study of AGT103-T has been published in Frontiers.
Today, we are excited to announce the winners of our 3rd Annual BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) and Greater Philadelphia life science communities and the individuals that make innovation happen.
In this role, Dr. Jain will lead the translational studies for the American Gene™ HIV cure clinical trial, developing scientific plans and overseeing the research. Specifically, she will be responsible for identifying the biomarkers, developing and validating assays, managing vendors for outsourced projects, analyzing the scientific data, and working with the team to understand the patient data and the clinical outcome of the HIV trials.
Jeff Galvin, the CEO of American Gene TechnologiesⓇ, one of the leading biotech companies in Maryland, has championed the state as “DNA Valley.” And Galvin should know: he came to Maryland after a successful career in Silicon Valley and sees parallels between the early days of an emerging Silicon Valley and what’s going on today in DNA Valley, which currently stretches from Montgomery County and Frederick, Maryland all the way up to Baltimore.
We’re excited to announce this year’s finalists for the third annual 2022 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
